Patrick Jimonet, Céline Druart, Stephanie Blanquet-Diot, Lilia Boucinha, Stephanie Kourula, Françoise Le Vacon, Sylvie Maubant, Sylvie Rabot, Tom Van de Wiele, Frank Schuren, Vincent Thomas, Bernard Walther, Michael Zimmermann
Human microbiomes, particularly in the gut, could have a major impact on efficacy and toxicity of the drugs. However, gut microbial metabolism is often neglected in the drug discovery and development process. Medicen, a Paris-based human health innovation cluster, has gathered more than thirty international leading experts from pharma, academia, biotech, CROs and regulatory affairs to develop proposals to facilitate integration of the microbiome in drug discovery and development. Seven subteams were implemented to cover the complementary expertise areas of 1) Pharma experience and case studies, 2) in silico microbiome-drug interaction, 3) in vitro microbial stability screening, 4) gut fermentation models, 5) animal models, 6) microbiome integration in clinical and regulatory aspects, and 7) microbiome standards...
February 2, 2024: Drug Metabolism and Disposition: the Biological Fate of Chemicals